Cardiovascular toxicity of carfilzomib, a last generation proteasome inhibitor, is highly incident according to retrospective data. Prospective cohort study of patients initiated on carfilzomib.
Study Type
OBSERVATIONAL
Enrollment
60
Assistance Publique Hôpitaux de Paris - Centre Université de Paris
Paris, France
RECRUITINGIncidence of cardio-vasculo-toxicity of carfilzomib
Number of patients with cardio-toxicity (composite endpoint) in a cohort of patients referred to a cardio-oncology before initiation of carfilzomib.
Time frame: 6 months
Systemic hypertension
Number of patients with as systemic hypertension
Time frame: 6 months
Heart Failure Reduced Ejection Fraction
Number of patients with Heart Failure and Reduced Ejection Fraction
Time frame: 6 months
Heart Failure Preserved Ejection Fraction
Number of patients with Heart Failure and Preserved Ejection Fraction
Time frame: 6 months
Predictors of Cardiotoxicity
Correlation between cardio-vascular toxicity and patients' chacateristics.
Time frame: 6 months
Impact on outcomes
Compare outcomes (mortality) in patients with cardiotoxicity and no cardiotoxicty.
Time frame: 1 year
Safety
Compare outcomes (mortality) in patients with cardiotoxicity according to the continuation of carflzomib or its withdrawl.
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.